Quell Therapeutics and eXmoor pharma have entered into a CAR-Treg manufacturing partnership.
Together, the companies will manufacture a portion of Quell's autologous CAR-Treg cell therapies, which are designed to treat a range of autoimmune diseases.
In the process, Quell will transfer its proprietary manufacturing process to eXmoor.
eXmoor will assist Quell in the process transfer, scale-out and clinical-stage manufacture of these candidates.
The company will also dedicate manufacturing capacity to Quell at its novel Cell & Gene Therapy Centre in Brisol, UK — which has recently received a GMP license from the MHRA.
Chief Manufacturing Officer at Quell Therapeutics, Aaron Vernon, said: “Building on our manufacturing experience producing QEL-001 for the LIBERATE clinical trial, this partnership will provide increased capacity to manufacture our emerging pipeline of CAR-Treg product candidates and move them into clinical development."
"Quell and eXmoor have worked productively and successfully together for several years, and we are excited to extend our relationship with them to support our clinical manufacturing needs.”
CEO of eXmoor pharma, Angela Osborne, added: “Quell’s CAR-Treg expertise and our long-standing collaboration make them an excellent first manufacturing client in our new, state-of-the-art facilities and we are committed to creating a true partnership,”
“eXmoor’s first cell therapy experience in 2007 was with Tregs so there is symmetry in this being the focus of our first manufactured products. Quell has made tremendous progress with its therapeutic programs and we are proud to be supporting them in accelerating the progression of their next-generation cell therapies into patient trials.”